Genzyme sells research line
This article was originally published in Clinica
Genzyme General is to divest its research products business to TECHNE for around $65 million before taxes. The purchase will consist of $24.8 million in cash, $17 million of TECHNE shares and estimated royalties of $23.7 million on TECHNE's biotechnology group sales for the next five years. The companies expect to close the transaction on July 1.